Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

456.81 +7.65 (+1.70%)
Streaming Delayed Price Updated: 10:03 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 118,098
Open 449.00
Bid (Size) 456.51 (160)
Ask (Size) 457.39 (160)
Prev. Close 449.16
Today's Range 449.00 - 460.92
52wk Range 205.87 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money ↗
No investment is a slam dunk to double your money. But these great stocks appear to have what it takes. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
+95.5%
+95.5%
1 Month
-5.2%
-5.2%
3 Month
-0.0%
-0.0%
6 Month
+56.5%
+56.5%
1 Year
+96.7%
+96.7%

More News

Read More
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
News headline image
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
Via Investor's Business Daily
Topics Death
News headline image
What Does the Market Think About Alnylam Pharmaceuticals Inc? ↗
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Via Benzinga
News headline image
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday? ↗
Via Benzinga
Topics Law Enforcement
News headline image
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings ↗
Via Chartmill
News headline image
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗
Via Benzinga
Topics Economy
News headline image
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗
Via Investor's Business Daily
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview ↗
Via Benzinga
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Via Benzinga
News headline image
Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest ↗
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Via Benzinga
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
News headline image
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗
Via Benzinga
News headline image
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 456.81
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 11/17/25 10:03 AM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 54.29B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 54B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.